24.04.2013 • News

Air Liquide Announces Q1 Results

Air Liquide Group revenue for the 1st quarter 2013 reached €3,698 million, down slightly (-2.1%) compared with Q1 2012, but stable (+0.2%) excluding currency and natural gas impacts.

Gas & Services sales reached €3,406 million. In a contrasted economic environment, the underlying activity was up +4.9%, driven by the pursuit of development initiatives in growing markets. Gas & Services sales rose on a comparable basis +9% in the developing economies.

Large Industries benefited from higher hydrogen demand for chemical plants and refineries in the United States and in China, and from start-ups and ramp-ups of new plants in Eastern Europe. Industrial Merchant activity was up slightly (+1%) on a comparable basis, while Electronics saw a recovery in equipment and installation sales in Japan.

Healthcare showed strong growth in all zones, reaching +12% at the global level and +13%in Europe, including the LVLMédical and Gasmedi acquisitions.

Efficiency gains reached €59 million for the quarter, in line with the annual objective of more than €250million. The Group is pursuing its efficiency efforts in its operations as well as by continuously adapting its structures.

Commenting on the 1st quarter 2013, Benoît Potier, Chairman and CEO of the Air Liquide Group, stated: "In an economic environment that remains contrasted, the 1st quarter saw the pursuit of growth investments and an increase in our underlying growth in Gas & Services by almost 5%. Boosted by the impact of acquisitions, the Healthcare activity is characterized by sustained growth of +12%.

The newly signed contracts, the planned commissioning of 50 units between 2013 and 2014, and the gradual ramp-up of plants that have started up in the past three years strengthen the Group's confidence in its ability to pursue growth over the mediumterm.

Barring a degradation of the environment, Air Liquide is confident in its ability to deliver another year of net profit growth in 2013."

 

 

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.